David Rind, ICER CMO

Up­dat­ed: ICER on Alzheimer's: lecanemab should be priced low­er than Aduhelm

Drug pric­ing watch­dog ICER said that the un­cer­tain­ty in the health ben­e­fits of two po­ten­tial Alzheimer’s drugs makes it chal­leng­ing to as­sess their fu­ture cost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.